Mide prekanseröz lezyonlarında klopidogrel kullanımının değerlendirilmesi: Kemopreventif etkisi var mı?

Abstract

Aims: Gastric malignancies are the third most common cause of cancer-related deaths. Although aspirin and clopidogrel have been reported to reduce the risk of colorectal cancer, their effects on gastric cancer are still under investigation. In this study, we aimed to determine whether clopidogrel has an effect on the development of gastric precancerous lesions. Methods: The study was designed as a retrospective case-control study. The study was conducted between January 2021 and April 2023 in the Gastroenterology Clinic of Samsun University Samsun Training and Research Hospital. Patients who underwent upper GIS endoscopy and biopsy examination due to dyspeptic complaints were scanned from the electronic data system of the hospital and their data were recorded by forming 4 groups as clopidogrel (89 patients), low-dose aspirin (ASA) (172 patients), non-aspirin non-steroidal anti-inflammatory drug (NA-NSAID) users (110 patients) and control group without antiplatelet use (110 patients). Statistical analyses were accomplished with SPSS for Windows v20.0. Results: Mean duration of drug use was 2 years for clopidogrel, 1.47 years for ASA and 0.35 years for NA-NSAID. The incidence of peptic ulcer was 7.2% in the control group, 38%, 15.1%, 49% in clopidogrel, ASA, NA-NSAID users, respectively (p